Venture_Socks_RZ_RGB_300dpi(2)_edited.pn
icon-prizes.png

WINNERS

orange arrows.png

Covagen

2006

Health & Nutrition

2000_W1_Carbofix.png
Sensirion_edited.jpg

Covagen are pioneers in the commercialization of Fynomers as next generation protein drugs to address unmet medical needs in inflammatory diseases and cancer. Fynomers represent a novel class of protein therapeutics. Covagen was acquired by Johnson & Johnson in 2014 for an undisclosed sum. It was Europe's largest acquisition in 2014.